Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Banco Santander S.A.

Banco Santander S.A. lessened its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 12.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 151,107 shares of the biopharmaceutical company’s stock after selling 21,124 shares during the period. Banco Santander S.A. owned approximately 0.10% of Ocular Therapeutix worth $1,290,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OCUL. Creative Planning acquired a new position in Ocular Therapeutix during the third quarter worth $182,000. Capital Performance Advisors LLP acquired a new position in Ocular Therapeutix during the third quarter worth $70,000. GSA Capital Partners LLP acquired a new position in Ocular Therapeutix during the third quarter worth $1,102,000. Intech Investment Management LLC acquired a new position in Ocular Therapeutix during the third quarter worth $422,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Ocular Therapeutix by 146.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock valued at $9,661,000 after purchasing an additional 660,080 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Activity

In other news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Donald Notman sold 6,301 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the transaction, the insider now owns 204,563 shares in the company, valued at $1,603,773.92. This trade represents a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,895 shares of company stock worth $283,772 over the last three months. 3.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Ocular Therapeutix currently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Ocular Therapeutix Stock Up 2.7 %

Ocular Therapeutix stock opened at $7.54 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.78. The stock’s fifty day moving average is $7.74 and its two-hundred day moving average is $8.86. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -5.71 and a beta of 1.34.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. Analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.